• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Cancer Trials Maintain Top Spot on 2020 List of Drug Research Areas

Cancer Trials Maintain Top Spot on 2020 List of Drug Research Areas

March 29, 2021

Oncology trials maintained their top spot on a list of 2020 trials, while the biggest increase in the number of trials was in the area of anti-infective drugs due to the monumental efforts to combat the COVID-19 crisis.

Informa Pharma Intelligence’s 2021 annual report shows that cancer drugs held the top four positions in the number of drug therapies being studied in 2020, with breast cancer coming in first at 924 drugs, followed by lung (710 drugs), colorectal (640 drugs) and pancreatic (563 drugs).

But COVID-19, with 553 drugs under trial, made its debut on the list of therapy areas at number five, moving ovarian, prostate and brain cancer down one spot each.

The study of anti-infective drugs saw the largest increase (22.4 percent) as of January 2021, the report found, noting that anti-infective trials were actually on the decline at the beginning of 2020.

Drug research has grown almost four-fold in the past 20 years, from 5,995 drugs in the trial pipeline in 2001 to 18,582 at the beginning of 2021. But the rate of growth took a hit in 2020, increasing by only 4.76 percent compared to 9.62 percent growth in 2019.

As of January 2021, there were 2,516 drugs in phase 1 trials, an increase of 6.4 percent over 2019, 2,694 in phase 2 (2 percent increase) and 1,020 in phase 3 (0.9 percent increase).

The 10 most active drug sponsors in 2020 were Novartis, Roche, Takeda Pharmaceuticals, Bristol Myers Squibb, Merck, Pfizer, Johnson and Johnson, AbbVie, AstraZeneca and Sanofi.

Read the full report here: https://bit.ly/31iMKfU.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing